Table 1 Characteristics of all study participants at baseline and missing study participants at T5
Intervention n = 77 | Intervention missing T5 n = 18 (23%) | Control n = 77 | Control missing T5 n = 8 (10%) | |
|---|---|---|---|---|
Female n (%) | 57 (74.0) | 13 (72.2) | 58 (75.3) | 6 (75.0) |
Age mean (±SD) | 61.8 (11.4) | 64 (9.5) | 59.3 (12.2) | 62 (11.9) |
Cancer type n (%) | ||||
Breast | 38 (49.4) | 8 (44.4) | 40 (51.9) | 4 (50.0) |
Colorectal | 20 (26.0) | 6 (33.3) | 18 (23.4) | 1 (12.5) |
Melanoma | 13 (16.9) | 2 (11.1) | 11 (14.3) | 1 (12.5) |
Gynaecologic | 3 (3.9) | 2 (11.1) | 2 (2.6) | 2 (25.0) |
Lung | 3 (3.9) | – | 6 (7.8) | – |
Hospital setting n (%) | ||||
Academic | 22 (28.6) | 7 (38.9) | 24 (31.2) | 2 (25) |
Non academic | 55 (71.4) | 11 (61.1) | 53 (68.8) | 6 (75) |
Cancer stage1 | ||||
0 | 2 (2.6) | – | 2 (2.6) | – |
I | 34 (44.2) | 6 (33.3) | 34 (44.2) | 5 (62.5) |
II | 22 (28.6) | 5 (27.8) | 27 (35.1) | 3 (37.5) |
III | 18 (23.4) | 6 (33.3) | 14 (18.2) | – |
IV | 1 (1.3) | 1 (5.6) | – | – |
Education | ||||
Low | 32 (41.6) | 9 (50) | 25 (32.5) | 1 (12.5) |
Middle | 13 (16.9) | 1 (5.6) | 18 (23.4) | 4 (50.0) |
High | 32 (41.6) | 8 (44.4) | 34 (44.2) | 3 (37.5) |
Number of comorbidities n (%) | ||||
None | 25 (32.5) | 4 (22.2) | 39 (50.6) | 2 (25.0) |
> 1 | 52 (67.5) | 14 (77.8) | 38 (49.4) | 6 (75.0) |
Number of GP practice contacts (year prior inclusion) median (IQR) | 7 (4.0;10.0) | 7 (6.0;11.5) | 6 (3.5;11.0) | 9 (3.5;12.0) |
GP years of working experience median (IQR) | 17 (12.0;25.5) | 17 (11.8;21.0) | 16 (10.5;24.5) | 18 (13.0;26.0) |
GP setting n (%) | ||||
Urban2 | 51 (66.2) | 10 (55.6) | 45 (58.4) | 6 (75.0) |
Between rural and urban3 | 14 (18.2) | 3 (16.7) | 15 (19.5) | 2 (25.0) |
Rural4 | 12 (15.6) | 5 (27.8) | 17 (22.1) | – |